Healthcare Providers and Services
Company Overview of N-of-One Therapeutics, Inc.
N-of-One Therapeutics, Inc. provides clinical analysis, curation, and interpretation of a tumor's molecular profile to providers, diagnostic companies, individual physicians, and cancer patients. The company’s solutions include treatment strategy roadmaps, clinical trial matching, and diagnostic strategy roadmaps. Its solutions and services pivot on matching patient-specific tumor molecular profiling data with knowledge on diagnostic technologies and therapeutic options to identify relevant clinical strategies for each patient's unique cancer. The company supports oncologists by delivering content and clinical insights for cancer treatment decisions and diagnostic approaches. N-of-One Therap...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One Therapeutics, Inc.
Chairman and Chief Executive Officer
Founder, President, Chief Medical Officer and Director
Vice President of Operations
Compensation as of Fiscal Year 2015.
N-of-One Therapeutics, Inc. Key Developments
CellNetix Pathology and Laboratories Utilizes N-of-One TrialMatch
May 26 15
N-of-One reported that CellNetix Pathology and Laboratories has adopted N-of-One's new clinical trial matching solution, TrialMatch, as well as N-of-One clinical interpretation evidence services. Under this agreement, N-of-One will provide clinical interpretation evidence as well as molecular profile-based clinical trial matching for CellNetix next generation sequencing cancer genomics tests.
N-of-One to Provide CNV Analysis Interpretation for Affymetrix’s OncoScan Kit
May 11 15
N-of-One has signed a business partner agreement to provide copy number variation (CNV) analysis interpretation for Affymetrix's OncoScan assay kit customers. Under the agreement, N-of-One will work closely with Affymetrix to ensure data from the OncoScan assay, combined with its interpretation, optimise the value of tumour profiling based on CNV analysis for clinicians. Based on Affymetrix's novel molecular inversion probe (MIP) technology, OncoScan assay helps in obtaining genome-wide copy number and loss-of-heterozygosity (LOH) profiles from degraded formalin-fixed, paraffin-embedded-derived tumour DNA samples.
N-of-One, Inc. Announces Executive Appointments
Dec 9 14
N-of-One, Inc. announced the appointment of two senior executives to support the company's rapid growth. The company has created two new positions: Vice President of Sales and Vice President of Operations. Mark Balsano joins N-of-One in the newly created position of Vice President of Sales. Previously, Mark was Vice President of Sales at Response Genetics. Mark is an experienced sales leader in clinical diagnostics and diagnostic testing. He will be working closely with current N-of-One customers as well as new health networks and diagnostic labs interested in N-of-One solutions and services. Dave Stowell joins N-of-One in the newly created position of Vice President of Operations. Previously, Dave was Senior Vice President of Client Services for Optum and, prior to that, Dave was at Picis, a high acuity EMR company, as Senior Vice President of Client Management and Client Operations. Dave brings many years of operational experience in healthcare, and has the skills and experience to grow team to meet market demand. At N-of-One, Dave will lead daily operations, product management, solution implementation, and ongoing client management and support.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|